Results 141 to 150 of about 21,178 (234)

Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes. [PDF]

Dermatol Ther (Heidelb)
Piraccini BM, Vañó-Galván S, Blume-Peytavi U, Ribet V, Mengeaud V.   +4 more
europepmc   +1 more source

GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6509-6532, August 2026.
ABSTRACT Aims To provide a comprehensive overview of the cardiovascular and renal effects of glucose‐dependent insulinotropic polypeptide (GIP) by integrating its physiological role with recent human trial data on tirzepatide, the first dual GIP and glucagon‐like peptide‐1 (GLP‐1) receptor agonist.
Michelantonio De Fano, Line L. Haurum, Christine R. Schwarz, Francesca Porcellati, Andreas Andersen   +4 more
wiley   +1 more source

Impact of Sleeve Gastrectomy Versus Intensive Lifestyle Modifications With Obesity Management Medications on BMI Trajectory and Target Attainment: A Prospective Matched Cohort Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7126-7136, August 2026.
ABSTRACT Aims To compare sleeve gastrectomy (SG) with intensive lifestyle modification combined with obesity management medications (ILM/OMMs) in adults with severe obesity, focusing on BMI trajectory, time to achieving clinically meaningful weight loss, and metabolic outcomes in a real‐world clinical setting.
Maria Francesca Russo, Giovanni Casella, Giulia Angelini, Sara Russo, James Casella‐Mariolo, Vito D'Andrea, Giulio Illuminati, Lidia Castagneto‐Gissey   +7 more
wiley   +1 more source

Rates of, Reasons for, and Reactions to Discontinuation of GLP‐1 Receptor Agonists: A Narrative Review

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6533-6549, August 2026.
ABSTRACT GLP‐1RAs are increasingly used for their glucose‐lowering and weight‐management effects, but many patients discontinue them. In this narrative review we aim to review real‐world, quantitative and qualitative GLP‐1RA discontinuation, adherence, and persistence evidence as it aligns with an established conceptual framework for understanding ...
Henry D. Heisey, L. Parker Gregg, Christopher D. Verrico, Dennis T. Villareal, Terri L. Fletcher   +4 more
wiley   +1 more source

Acute GIP and GLP‐1 Administration Exerts Differential Metabolic Effects in Totally Pancreatectomised Individuals

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7280-7290, August 2026.
ABSTRACT Aims While being recognised for stimulating pancreatic insulin secretion, GIP and GLP‐1 exert various extrapancreatic effects relevant in the context of incretin‐based therapies. Here, we evaluated the extrapancreatic effects of GIP and GLP‐1, separately and combined, on postprandial physiology in totally pancreatectomised individuals ...
Liva S. L. Krogh, Maja B. Hansen, Natasha C. Bergmann, Carsten P. Hansen, Bolette Hartmann, Jens J. Holst, Filip K. Knop, Asger B. Lund, Lærke S. Gasbjerg   +8 more
wiley   +1 more source

Chronic Glycaemic Control Modulates the Relationship Between GIP and Glucagon Secretion Following Oral and Enteral Nutrients in Type 2 Diabetes. [PDF]

Diabetes Obes Metab
Wang Z, Huang W, Rasmussen RS, Horowitz M, Jones KL, Rayner CK, Xie C, Wu T.   +7 more
europepmc   +1 more source

ANXA1‐Derived Peptide Increases Melanoma Cell Sensitivity to Vemurafenib by Downregulating EphA2

Journal of Cellular and Molecular Medicine, Volume 30, Issue 16, August 2026.
ABSTRACT Vemurafenib (VEM) is a BRAF inhibitor that improves the prognosis of melanoma, but acquired resistance represents a key limitation to its clinical efficacy. This study investigated the potential of A11, an Annexin A1 (ANXA1)‐derived peptide, to enhance VEM efficacy in both VEM‐sensitive and VEM‐resistant melanoma cells.
Juan Feng, Xiao‐Pu Huang, Ming Zhang, Wei Huang, Shan‐Shan Lu, Zhi‐Qiang Xiao, Zhi‐Hai Xie, Hong Yi   +7 more
wiley   +1 more source

Tail-Suspension Model of Simulated Microgravity-Induced Functional Dyspepsia in Rats: Behavioral, Motility, and Brain-Gut Peptide Alterations. [PDF]

Int J Mol Sci
Li W, Li Y, Wang F, Qi H, Fan B, Wang G, Wang Q.   +6 more
europepmc   +1 more source

Dermatological, Trichological and Quality of Life Consequences of GLP‐1 Receptor Agonist‐Mediated Weight Loss: A US Cross‐Sectional Survey

Journal of Cosmetic Dermatology, Volume 25, Issue 8, August 2026.
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), including dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide (GLP‐1/GIP) receptor agonists, have revolutionized obesity management, resulting in significant medication‐driven weight loss (MDWL). Despite widespread reporting, the dermatological consequences
Janet Wangari Olivero, Jyotsna Paturi, Magali Moreau, Kun Qian, Stacy‐Ann Stevenson, Yaxian Zhen, Qian Zheng   +6 more
wiley   +1 more source

A randomised clinical trial testing the safety of and metabolic responses to short-term duodenal infusion of recombinant RORDEP1 in healthy men. [PDF]

Diabetologia
Gæde J, Fan Y, Lyu L, Gasbjerg LS, Rossing P, Hartmann B, Holst JJ, Lund AB, Knop FK, Pedersen O.   +9 more
europepmc   +1 more source